Use of Alpelisib for Patients with PIK3CA-mutated advanced Breast Cancer

被引：0
|
作者：
Malter, Wolfram [1 ]
Alakus, Hakan [2 ]
Mallmann, Peter [1 ]
Bruns, Christiane [2 ]
机构：
[1] Univ Cologne, Uniklin Koln, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Cologne, Germany
[2] Univ Cologne, Uniklin Koln AoR, Klin & Poliklin Allgemein Viszeral & Tumorchirurg, Kerpener Str 62, D-50937 Cologne, Germany
来源：
ONKOLOGE | 2019年 / 25卷 / 08期
关键词：
D O I：
10.1007/s00761-019-0619-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：724 / 725
页数：2
相关论文
共 50 条
  • [41] Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women
    Phipps, Amanda I.
    Makar, Karen W.
    Newcomb, Polly A.
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2013, 28 (12) : 1637 - 1642
  • [42] Alpelisib-Induced Hyperglycemia in PIK3CA+ Breast Cancer Patients
    Annoor, Anika
    Rahman Marzan, Mariya
    Iqbal, Raisa Binte
    Ferdausi, Aysha
    Yasmeen, Arowa
    Tarannum, Parisa
    John, Preethi
    SOUTHERN MEDICAL JOURNAL, 2025, 118 (02) : 97 - 101
  • [43] Effectiveness of Alpelisib plus Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer
    Turner, Stuart
    Chia, Stephen
    Kanakamedala, Hemanth
    Hsu, Wei-Chun
    Park, Jinhee
    Chandiwana, David
    Ridolfi, Antonia
    Yu, Chu-Ling
    Zarate, Juan Pablo
    Rugo, Hope S.
    ONCOLOGIST, 2021, 26 (07): : E1133 - E1142
  • [44] Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited
    Daniella C. N. Hall
    Ralf A. Benndorf
    Cellular and Molecular Life Sciences, 2022, 79
  • [45] Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer
    Kodahl, Annette R.
    Ehmsen, Sidse
    Pallisgaard, Niels
    Jylling, Anne M. B.
    Jensen, Jeanette D.
    Laenkholm, Anne-Vibeke
    Knoop, Ann S.
    Ditzel, Henrik J.
    MOLECULAR ONCOLOGY, 2018, 12 (06): : 925 - 935
  • [46] Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited
    Hall, Daniella C. N.
    Benndorf, Ralf A.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2022, 79 (07)
  • [47] Combination of the PLK1 Inhibitor Onvansertib and the PI3Kα Inhibitor Alpelisib Overcomes Palbociclib Resistance in PIK3CA-mutated HR plus Breast Cancer
    Sreekumar, Sreeja
    Painsec, Pierre
    Klein, Davis
    Gonzalez, Dalia
    Sourd, Laura
    Montaudon, Elodie
    Smeal, Tod
    Marangoni, Elisabetta
    Ridinger, Maya
    CANCER RESEARCH, 2024, 84 (09)
  • [48] Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR) [+]/HER2[-] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA
    Llombart Cussac, A.
    Perez-Garcia, J. M.
    Blanch, S.
    Tolosa, P.
    Ruiz Borrego, M.
    Gion Cortes, M.
    Fernadez, A.
    Urruticoechea, A.
    Galve, E.
    Cueva Banuelos, J. F.
    Ponce, J.
    Alonso, J. L.
    Capelan, M.
    Martinez, E.
    Bermejo De Las Heras, B.
    Rojas, B.
    Martos, T.
    Lopez, A.
    Gomez-Peralta, F.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S77 - S77
  • [49] Network Analysis Reveals A Signaling Regulatory Loop in PIK3CA-mutated Breast Cancer Predicting Survival Outcome
    Shauna R.McGee
    Chabane Tibiche
    Mark Trifiro
    Edwin Wang
    Genomics,Proteomics & Bioinformatics, 2017, (02) : 121 - 129
  • [50] Alpelisib Extends PFS in PIK3CA-Mutant Breast Cancer
    Dolgin, Elie
    CANCER DISCOVERY, 2019, 9 (01) : 6 - 7
12345